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Abstract
Alcohol is the most commonly abused legal substance and alcoholism is a serious public health 
problem. It is a leading cause of preventable death in the world. The cellular and molecular 
mechanisms of alcohol reward and addiction are still not well understood. Emerging evidence 
indicates that unlike other drugs of abuse, such as nicotine, cocaine, or opioids, alcohol targets 
numerous channel proteins, receptor molecules, and signaling pathways in the brain. Previously, 
research has identified brain nicotinic acetylcholine receptors (nAChRs), a heterogeneous family 
of pentameric ligand-gated cation channels expressed in the mammalian brain, as critical 
molecular targets for alcohol abuse and dependence. Genetic variations encoding nAChR subunits 
have been shown to increase the vulnerability to develop alcohol dependence. Here, we review 
recent insights into the rewarding effects of alcohol, as they pertain to different nAChR subtypes, 
associated signaling molecules, and pathways that contribute to the molecular mechanisms of 
alcoholism and/or comorbid brain disorders. Understanding these cellular changes and molecular 
underpinnings may be useful for the advancement of brain nicotinic–cholinergic mechanisms, and 
will lead to a better translational and therapeutic outcome for alcoholism and/or comorbid 
conditions.
1. INTRODUCTION
Alcohol is the most commonly abused legal substance by humans. Alcoholism is a complex 
and chronic relapsing disorder that represents a serious global public health problem.1 
Alcoholism related deaths are estimated to account for 4% of all deaths worldwide and this 
number will be higher in the coming decades.2 The prevalence of fetal alcohol syndrome, 
caused by mother’s alcohol abuse and dependence, is also a significant problem in the 
United States and other industrialized nations.3 The estimated healthcare and economic cost 
from alcohol abuse and alcoholism in the United States, is significantly higher than many 
other diseases, including cancer.4 Thus, there is a need for better understanding of this 
complex brain disorder, for better therapeutic approaches to reduce alcohol abuse and 
relapse. Like nicotine addiction, emerging evidence suggests that neuronal nicotinic 
acetylcholine receptors (nAChRs), in the mesocorticolimbic-dopamine system, mediate the 
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rewarding effects of alcohol and the development of alcohol dependence.5–9 Therefore, 
nAChRs are potential molecular targets for alcohol abuse and alcoholism. The primary focus 
of this review is to provide new insights into the rewarding effects of alcohol, as they pertain 
to different nAChR subtypes and other cholinergic factors that contribute to the molecular 
mechanisms of alcoholism. Understanding these cellular changes and molecular 
underpinnings, will lead to a better translational and therapeutic outcome of alcoholism. 
Considering the diversity of nAChRs in the brain, this chapter will discuss the role of 
different nAChR subunits, involving alcohol abuse and alcoholism obtained from genetic, 
preclinical, and clinical studies. In addition, the role of nAChRs in alcohol, nicotine 
coabuse, and other comorbid brain disorders will be discussed. The molecular targets and 
neurobiological mechanisms within the nAChRs system may offer a better understanding 
and effective therapeutic alternative to combat this complex relapsing brain disorder.
2. MESOLIMBIC-DOPAMINE SYSTEM AND nAChRs
Genetic, preclinical, and clinical studies have identified the brain nAChRs and membrane 
bound ion channels in the mesolimbic-dopamine system, as being involved in alcohol 
dependence.10–18 The nAChRs are pentameric ligand-gated cation channels with a diverse 
composition, which is widely expressed throughout the central nervous system (CNS).19–22 
The nAChR-mediated signaling plays a critical role in many drug addiction processes, 
including the development of alcoholism.23–27 Twelve neuronal nAChR subunits, which are 
classified as either alpha subunits (β2–β10) or beta subunits (β2–β4), have been 
identified.19,28–31 These subunits assemble to form diverse functional nAChRs, which can 
be further subdivided into two major groups of brain nAChR subtypes.23,24,27 For example, 
heteromeric receptors are assembled from both alpha (β2–β6) and beta subunits. The 
functional properties of such heteromeric receptors, depend on both the specific β and β 
subunits within the receptor complex and the β:β ratio of the subunits.28–31 Previous 
research indicates that the most abundant nAChRs in the CNS are β4β2★, receptors 
containing both β4 and β2 subunits, and sometimes additional subunits (denoted by the 
asterisk). These receptors account for >90% of the high affinity nicotine binding sites in the 
brain.30 The β4 and β2 subunits are colocalized in many parts of the brain, including 
thalamic nuclei, cortex, and ventral striatum.19,30
On the other hand, homomeric receptors, such as, β7 nAChR subtypes, are predominantly 
located in the hippocampal regions and cortical or subcortical regions, including the ventral 
striatum.31 In addition, neuronal nAChRs containing β6 subunits are expressed in dopamine-
rich areas (e. g., the mesocorticolimbic reward neurocircuit). Thus, β6★ receptors may be a 
new/novel drug target to treat many forms of drug addiction, including alcohol 
dependence.25 A number of invitro or invivo studies have confirmed that alcohol activates 
the mesolimbic-dopamine system and elevates the synaptic release of dopamine in the 
ventral striatum, which partially mediates the rewarding effects of alcohol and other drugs of 
abuse.32–35 Therefore, mesocorticolimbic nAChRs are considered to be a molecular switch, 
activated by addictive behaviors.9,15,36–38 Neuronal nAChRs are widely expressed at the 
synapse, cell body, and axons in the CNS.21 Presynaptic nAChRs are involved in regulating 
the release of ACh, monoamines, and amino acids.39–43 In particular, dopamine release is 
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regulated by β4β2★, β3β2★, and β6★ nAChRs (★ indicates a possible involvement of other 
receptor subunits) in nigrostriatal/mesocorticolimbic terminals.44–47
3. KNOCKOUT AND TRANSGENIC MODELS AND nAChRs
Recent reports with nAChR subtype knockout (KO) mice have provided important 
information about both brain nAChR function and the mediation of addiction-related 
behavior.23,48,49 For example, early research showed that mice lacking the β2 subunit do not 
display too many nicotine-associated responses, including nicotine-induced DA release in 
the dorsal and ventral striatum, as well as nicotine-elicited increases in the firing rate of 
associated DA neurons.50,51 The lack of nicotine effect on the mesolimbic DA systems in β2 
subtype nAChR KO mice is consistent with the absence of nicotine self-administration by 
these animals.51 The β4 subunit requires a β2 subunit for assembly in a majority of 
heteromeric nAChRs in the brain. These and other studies using genetically modified mice 
suggest that β4/β2★ nAChRs are critical for nicotine-related reward behaviors.52,53 Despite 
the distribution of the β7 subunit in the brain, in particular its presence in the 
mesocorticolimbic system, studies in β7 KO mice are not definitive about a role for the β7 
subunit in nicotine reward and conditioning.48 However, β7★ nAChRs are important for 
long-term potentiation, neuroplasticity associated with learning, and memory in the 
mesolimbic reward pathway.48 KO mouse studies targeting the β6 subunit indicate that β6 
partners with β2 nAChRs and may play an important role in nicotine addiction related 
behavior.54 Like nicotine addiction, genetic studies have revealed that nAChRs are involved 
in ethanol self-administration, and reward behavior as well.11 For example, a number of 
genetic studies have been conducted to identify the role of nAChR subtypes in ethanol-
drinking behavior. Acute ethanol drinking behavior is reduced in β4 KO mice, compared to 
wild type (WT), indicating a role for the nAChR β4★subunit in ethanol abuse.11,26 
Similarly, ethanol-related behavior and ethanol-induced midbrain dopaminergic function get 
decreased in β4 KO mice.55 On the other hand, β2 KO mice behave similar to WT type mice 
in ethanol drinking behaviors.56 In addition, β6 KO and β3 KO mice also display ethanol 
drinking behavior that is similar to WT mice in a two-bottle ethanol drinking paradigm.56 
Moreover, β7 KO and WT mice consume similar amounts of ethanol, although there was a 
potential gender effect regarding β7 nAChRs effects on ethanol consumption.56 Again, β5 
KO mice do not differ in acute ethanol consumption, compared to WT mice.57 Like 
nicotine-related behavior (as mentioned earlier), studies with transgenic over expression of 
the β5, β3, and β4 receptor subunit genes indicate these subunits have a complex role in the 
modulation of ethanol-related behaviors.58 Together, these data indicate that nAChRs 
containing β5, β6, β2, or β3 subunits may not be critical in ethanol drinking behaviors. 
Overall, the evidence suggests that β4 receptors in the midbrain may be essential for 
ethanol-related behavior. These studies represent genetic mechanisms in ethanol 
dependence, involving brain nAChRs and associated neurobiological mechanisms.
It is widely recognized that brain nAChR subtypes are important mediators of the rewarding 
effects of ethanol and drugs of abuse.55,59–66 For example, systemic or local administration 
of nAChR ligands reduce ethanol drinking in a number of animal models.32,60,61,65 
Furthermore, nAChRs in the ventral tegmental area (VTA) regulate ethanol consumption 
and associated mesolimbic neurochemical effects (e.g., dopamine release in the nucleus 
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accumbens (Acb)), as shown in various preclinical studies.60,62 However, some of these 
ligands produce mixed effects in alcohol/ethanol drinking behavior in humans,59,63 
indicating mixed efficacy for treating ethanol dependence through nAChRs in the 
mesolimbic-dopamine system. Similarly, specific nAChR ligands may be resistant to 
pharmacologically efficacious reductions in ethanol drinking behavior, thus suggesting a 
role for other nAChR targets, such as β6β2★.33,36 Additional studies with the β7 nAChR 
ligand were found to be ineffective in reducing ethanol-taking behavior of animal models.56 
In other works, a partial β4β2★ nAChR agonist was shown to reduce alcohol drinking in 
both animal models and humans.16,26,56,65,67–75 Given the mixed results with 
pharmacological efficacy on ethanol drinking behavior, the role of specific nAChR subtypes 
needs further investigation. Additional studies with cytisine, a partial agonist at β4β2★ and 
lobeline, which is a nonselective antagonist, were found to reduce ethanol-taking behavior in 
a number of preclinical models.17,66,73–77 Interestingly, these nAChR ligands also altered 
alcohol-induced increases in mesolimbic tissue DA levels in mice,77 supporting the 
important role of mesolimbic nAChRs in alcohol dependence. Confirming this, the nAChR 
ligands were found to reduce ethanol-taking behavior in a genetic animal model for alcohol 
abuse and dependence78 or inbred mice,74 indicating nAChRs are potential molecular 
targets for individuals with a genetic predisposition to develop alcohol dependence.
Thus, evidence suggests that selective desensitization of nAChRs with partial agonistic 
activity79,80 reduces ethanol-taking behavior in rats selectively bred for an alcohol 
preference.80,81 In addition with the involvement of nAChRs in ethanol-taking behavior, 
some of these ligands26,75,81,82 also decrease the alcohol deprivation effect, which is an 
animal model of relapse behavior.78,83–87 Emerging preclinical studies suggest that nicotine 
exposure reinstates alcohol seeking behaviors in rodents following extinction of alcohol 
reinforcement.88,89 Therefore, examination of cholinergic mechanisms associated with 
relapse is also important for new drug development to treat ethanol abuse and 
dependence.5,90 Overall, the existing animal and human studies suggest that ethanol-induced 
activation of the mesolimbic DA system involves brain diverse nAChRs stimulation, 
including β4β2★, β6β2★, as well as β3β4★ subtypes.91 Thus, central nAChRs continue to be 
critical targets for the reinforcing and DA-activating effects of ethanol and underscore the 
need to conduct more subunit-specific nAChR research regarding ethanol abuse and 
dependence.
4. ALCOHOL, NICOTINE COABUSE, AND nAChRs
Due to the prevalence of ethanol and nicotine couse,92 and the extremely high rates of 
smoking in individuals diagnosed with alcohol dependence,93,94,95 investigators have been 
working to develop models of coabuse in animals. However, till date very few such models 
have been validated. In one such model, within-session intravenous nicotine and oral ethanol 
drinking was demonstrated in Wistar rats.96 More recently, ethanol-preferring (P) rats show 
oral operant intake of combined ethanol and nicotine solutions, that results in blood ethanol 
concentrations of approximately 100 mg% and blood nicotine levels of approximately 25 
ng/mL. These levels are similar to levels obtained in human binge drinking and smoking.97 
Additionally, in adolescent C57BL/6 mice, exposure to cigarette smoke for 6 h/day for 16 
days increased intake of 10% ethanol three to five fold in a scheduled access paradigm.98 
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Also, chronic nicotine exposure in C3H mice during adolescence enhances ethanol 
withdrawal effects in adulthood.99
In a study using rats selectively bred for high versus low locomotor activity induced by a 
novel field, it was found that adolescent exposure to nicotine facilitated an ethanol-induced 
conditioned place preference in early adulthood.100 Regarding β4β2★ receptors, a recent 
study revealed that chronic ethanol exposure/intake, including in utero exposure, by rhesus 
monkeys significantly decreased β4β2★ levels in the frontal and insular cortex.101 In a study 
involving in utero exposure of rats, it was found that gestational exposure to ethanol and 
nicotine significantly increased nicotine self-administration during adolescence, and this 
effect seemed to be due to glutamatergic modulation of the mesolimbic-dopamine 
system.102 These data suggest a possible interaction between stages of development and 
cigarette smoke/nicotine exposure to increase ethanol and/or nicotine intake through 
different mechanisms that may extend into adulthood.
Animals selected for ethanol preference also show an increased sensitivity to the reinforcing 
effects of various drugs, including nicotine.97 For instance, the P rat shows elevated 
sensitivity to the self-administration of intravenous nicotine, compared to the nonpreferring 
(NP) rat.103 Consistent with this finding, P-rats are more sensitive than Wistar rats to the 
self-administration of nicotine directly into the posterior ventral tegmental area (pVTA) 
using the intracranial self-administration technique,104 and ethanol and nicotine are co-self-
administered into the pVTA at low concentrations that do not support self-administration 
individually.105 However, in a recent study employing DBA/2J mice, nicotine was found to 
enhance the locomotor stimulating, but not the conditioned rewarding effects of ethanol, 
suggesting that in this model, combined stimulant effects of nicotine and ethanol do not 
predict enhanced reward.106,107
Overall, current data suggest that ethanol and nicotine coabuse is rooted in the basic 
biological underpinnings of both drugs, supposedly by targeting β4β2★ nAChR subtype in 
the mesolimbic-dopamine system. The drugs may function synergistically on some measures 
and each drug affects the other in terms of abuse liability. Emerging findings would suggest 
that the selection of ethanol-preference may increase the potential intake of nicotine 
coabuse, and adolescent coabuse may be lead to elevated levels of coabuse in adulthood. 
Additional studies are clearly needed to provide a better understanding of the mechanisms 
that are involved in ethanol and nicotine coabuse.
5. GENETIC POLYMORPHISMS, ALCOHOL DEPENDENCE AND nAChRs
Emerging evidence indicates that cholinergic genes may play a significant role in ethanol-
dependent behavior.108 For example, significant associations between CHRNA6 
polymorphisms (rs1072003, rs2304297, and rs892413) as well as CHRNB3 polymorphism 
(rs13280604) and excessive ethanol-drinking behavior have been reported.109 In a recent 
study, using Hispanic and non-Hispanic white subjects from the Social and Emotional 
Contexts of Adolescent Smoking Patterns, revealed multiple polymorphisms of CHRNA4 
were associated with a significantly elevated risk for adolescent binge drinking.110 These 
authors reported that polymorphisms for other nAChR genes were not associated with this 
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risk, which may be related to the ethnicity of the sample. Additional studies from the 
Nicotine Addiction Genetics consortium in Finland, reported a significant association 
between the CHRNB4 polymorphism rs11636753 and regular ethanol drinking with 
comorbidity for depression, which may have been sex dependent.111 Regarding addiction in 
general, although polysubstance abuse may be a factor, the CHRNA5 risk polymorphism 
(rs16969968) is not only associated with nicotine dependence,112 but also associated with 
other drugs of abuse, such as cocaine.113 Similarly, other CHRNA5 polymorphisms 
(rs615470 and rs684513) have significant associations with ethanol and cocaine dependence, 
respectively.113 Given an early onset of ethanol, drug use and abuse increases the 
probability of developing dependence later in life, it is important to examine whether these 
effects are under genetic control. One studyexamining polymorphisms within the CHRNA5-
A3-B4 gene cluster found a significant association with the age of initiating the use of 
multiple abused substances.114 Similarly, recent findings from the San Diego Sibling Pair 
study indicate that, variants for CHRNA5 within this cluster are significantly associated with 
subjective level of response (i.e., intoxication) to ethanol.115 Interestingly, a recent study 
indicated missense variants in CHRNA3 may confer resistance to cocaine dependence in 
African Americans.116 However, it was also reported that a missense variant in CHRNB3 
called rs149775276, was significantly associated with ethanol and cocaine dependence in 
European Americans.116 Combined findings indicate that multiple polymorphisms 
associated with nAChR genes and addictions, have been identified. Moreover, these 
associations predict dependence on a number of abused substances and/or associated 
behaviors, across national, ethnic, and psychiatric groups. Taken together, these studies 
suggest that nAChRs could be important targets for the development of therapeutics 
targeting multiple addictions, including alcoholism.
6. ALCOHOL DEPENDENCE, COMORBID PSYCHIATRIC CONDITION AND 
nAChRs
Recent evidence indicates that nAChRs are involved in drug addiction and comorbid 
psychiatric disorders, such as anxiety or depression.117 Just as in nicotine addiction,118 it has 
been proposed that there is a relationship between ethanol dependence and 
depression.119,120 For example, patients with depression have higher rates of ethanol-related 
problems, than the general population.121,122 Ethanol abstinence-related depression 
increases the chance of relapse because people may use ethanol for self-medication.123 A 
number of studies have determined how genetic predisposition to high ethanol intake affects 
depression-like behavior, and how genetic predisposition to depression-like behavior affects 
ethanol intake in rats, but the results are not well established,124 probably due to the 
challenges of defining criteria for valid animal models of these disorders. Previous studies 
suggest that chronic ethanol consumption in mice increases depression-like behavior during 
abstinence from ethanol.125,126 Therefore, alcoholism and depression supposedly share 
common molecular targets and associated neurobiological mechanisms. For example, 
abstinence from ethanol increases ACh release in the Acb,127 and microdialysis studies 
indicate that ethanol abstinence induces rapid and sustained increases in extracellular ACh 
levels in the hippocampus.128 A reduction in serotonergic neurotransmission has also been 
implicated in subpopulations of alcoholic patients.129,130 And, the efficacy of selective 
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serotonin reuptake inhibitors (SSRIs) provides strong support for the role of serotonin in 
depression, although SSRI treatment efficacy is highly variable for maintaining long-term 
abstinence from ethanol.131 Alcoholism,132 nicotine addiction,133 and depression134,135 are 
disorders mediated by neuroplasticity including transcriptional control, especially with 
brain-derived neurotrophic factor (BDNF) and activity-regulated cytoskeleton-associated 
protein (Arc)136 pathways. Regarding this, prolonged exposure to and abstinence from 
ethanol causes long-lasting neuroadaptations, which may underlie the development of 
depression-like behavior.126 Moreover, chronic ethanol consumption reduces the expression 
of BDNF in the rat hippocampus, which is an effect seen in depression-like behavior in 
animal models.137 Given the common neurobiological mechanisms in ethanol dependence 
and comorbid depression, it is possible that β2★-nAChRs modulation and associated 
molecular mechanisms will be critical in reducing depression, in the presence of ethanol 
abuse and dependence. Therefore, the contribution of specific nAChR subtypes, and their 
molecular signaling in comorbid conditions, needs considerable additional investigation.
7. ALCOHOL, TRANSCRIPTION FACTORS, AND nAChRs
Evidence indicates that nAChRs modulate acute ethanol-induced increased expression of 
Fos family in the immediate early genes, such as c-Fos in midbrain dopaminergic 
neurons.17,26 In addition, both partial agonists and antagonists targeting nAChRs, reduce 
acute ethanol-induced c-Fos expression in the VTA and Acb.17,26 Similarly deltaFosB, 
which is a truncated splice variant of FosB gene, activity is associated with chronic ethanol 
exposure and neuroplasticity in the mesolimbic reward neurocircuit.138,139,140,141 Also, 
recent research suggests that nAChRs modulate deltaFosB upregulation in both ventral and 
dorsal striatum.76 For example, partial agonists at nAChRs reduce chronic ethanol drinking 
behavior and its associated striatal deltaFosB upregulation.76 Overall, these studies support 
the possible role of nAChRs in modulating long-lasting behavioral and molecular 
neuroadaptations that may be related to alcoholism. However, the role of nAChRs on other 
important transcription factors, such as cAMP-responsive element binding (CREB) 
expression requires further investigation.142,143
8. CONCLUSIONS
In this review, evidence has been presented for the fact that AChRs in the mesolimbic-
dopamine system are important molecular targets for ethanol abuse and alcoholism. It is 
evident from in vitro and in vivo studies that nAChRs are critically involved with synaptic 
activity of mesolimbic dopa-mine as well as associated cellular and molecular mechanisms, 
which underlie the addictive properties produced by ethanol. Given the variety of nAChR 
subtypes, localization and functions of these nAChRs are potential mediators of the complex 
neurobiological effects of ethanol. While the nAChR subtypes share a common structure, 
their pharmacological properties on drug addiction, including models of alcoholism, may 
depend on nAChR subunit composition. We believe that multiple nAChR subtypes could be 
targets for neurobiological effects of ethanol and their contribution to alcoholism. Therefore, 
understanding subtype-selective mechanisms will be critical for future translational research. 
Thus, brain nAChRs represent a potential molecular target for treating ethanol abuse and 
dependence. The fact that ethanol and nicotine addiction often cooccur in humans, is widely 
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recognized in this literature. Recent evidence indicates a genetic corelation between these 
two addictive disorders. Preclinical and clinical studies suggest that both nicotine and 
ethanol can, either directly or indirectly, activate the mesolimbic-dopamine system, which 
putatively mediates the rewarding effects and ethanol-induced addictive behavior, associated 
with nAChRs. Emerging data also indicate that neuronal nAChRs are involved in addiction 
and comorbid psychiatric disorders, such as anxiety or depression. Finally, it is important to 
note that nAChRs modulate important transcription factors, such as c-Fos or deltaFosB, in 
the mesolimbic-dopamine system that may be associated with chronic effects of ethanol. 
However, the role of nAChRs on CREB or BDNF expression associated with alcoholism 
remains to be determined. Overall, the evidence supporting a role for nAChRs in the 
neurobiological effects of ethanol is significant from a translational perspective, as are the 
implications of nAChRs in addictive behaviors, and a variety of comorbid psychiatric and 
cognitive conditions. Additional research and a refined understanding of the specific 
contribution of nAChR subtypes, and associated neurobiological mechanisms involving 
alcoholism and comorbid neuropsychiatric conditions, may identify new molecular targets 
and signaling pathways for the development of better treatment and prevention strategies.
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